3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Address of Principal Executive Offices) (888) 969-7879 (Registrant's Telephone number including area code) N/A | | UNITED STATES | | --- | --- | | | SECURITIES AND EXCHANGE COMMISSION | | | WASHINGTON, D.C. 20549 | | | _________________________________ | | | FORM 10-Q | | | _________________________________ | | ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the quarterly period ended June 30, 2022 ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Chris Cline – Senior Vice President-Investor Relations Eric Dube – Chief Executive Officer Jula Inrig – Chief Medical Officer Peter Heerma – Chief Commercial Officer Laura Clague – Chief Financial Officer Bill Rote – Senior Vice President-Research & Development Conference Call Participants Carter Gould – Barclays Mary Kate Davis – Bank of America Liisa Bayko – Evercore ISI Maury Raycroft – J ...

| | UNITED STATES | | --- | --- | | | SECURITIES AND EXCHANGE COMMISSION | | | WASHINGTON, D.C. 20549 | | | _________________________________ | | | FORM 10-Q | | | _________________________________ | | ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the quarterly period ended March 31, 2022 | | | or | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the transition period from ___________ to ________ ...

Travere Therapeutics Corporate Overview March 2022 © 2021 Travere Therapeutics, Inc. Forward-Looking Statements 2 This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings and agency actions, and the anticipated development, timing, data readouts and therapeutic scope of programs in our clinical pipeline. These forward- looking statements may be accompanied by such words as "anticipate," " ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Chris Cline - SVP, IR & Corporate Communications Eric Dube - CEO Jula Inrig - CMO Peter Heerma - CCO Laura Clague - CFO Bill Rote - SVP of Research & Development Conference Call Participants Greg Harrison - Bank of America Joseph Schwartz - SVB Leerink Maury Raycroft - Jefferies Michelle Gilson - Canaccord Genuity Liisa Bayko - Evercore ISI Laura Chico - Wedbush Operator Good day and t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-4842691 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 (Address of Principal Executive Offices) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fi ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2021 Earnings Conference Call October 28, 2021 4:30 PM ET Company Participants Chris Cline - SVP, IR & Corporate Communications Eric Dube - CEO Noah Rosenberg - CMO Peter Heerma - CCO Laura Clague - CFO Bill Rote - SVP, Research & Development Conference Call Participants Maury Raycroft - Jefferies Greg Harrison - Bank of America Joseph Schwartz - SVB Leerink Michelle Gilson - Canaccord Genuity Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Operator Go ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact na ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2021 Results Conference Call July 29, 2021 4:30 PM ET Company Participants Chris Cline - SVP, IR & Corporate Communications Dr. Eric Dube - CEO Dr. Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - CFO Dr. Bill Rote - SVP, Research and Development Conference Call Participants Joseph Schwartz - SVB Leerink Liisa Bayko - Evercore ISI Tim Lugo - William Blair Greg Harrison - Bank of America Michelle Gilson - Canaccord Maury ...

| UNITED STATES | | --- | | SECURITIES AND EXCHANGE COMMISSION | | WASHINGTON, D.C. 20549 | _________________________________ FORM 10-Q _________________________________ ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-36257 TRAVERE THERAPEUTICS, ...